Important NoticeThis app is for educational purposes only. You must be 18+ to use it. We do not sell any peptides on this site.

Research Use Only - Important Disclaimer

All products listed on this website are intended for laboratory research use only and are not for human consumption, medical, veterinary, or household use. These products should only be handled by qualified professionals. We do not provide any dosage information, and the products must not be used as food additives, drugs, cosmetics, or for any other inappropriate applications. By purchasing, you acknowledge and agree to these terms.

Vial

ACE-031

Soluble Activin Type IIB Receptor–Fc Fusion (Myostatin/Activin Ligand Trap)For research use only
View

ACE-031 (ActRIIB-Fc Ligand Trap) is a recombinant fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1…

Half-life

Approximately 10–15 days (human PK, single-dose SC)

Delivery

Subcutaneous injection; historical clinical protocols dosed every 2–4 weeks.

Suggested dosage

Not specified

Usage

Used to study muscle-wasting disorders, sarcopenia/cachexia models, bone mass regulation, and downstream metabolic/functional outcomes (lean mass, strength, BMD).

Mechanism of action

Ligand trap that sequesters myostatin and select activins from ActRIIA/B receptors, attenuating TGF-β/SMAD2/3 signaling; results include increased muscle protein synthesis/hypertrophy and bone accrual.

Benefits (3)

  • Increases lean body mass and muscle volume in human and animal studies
  • May improve functional measures (e.g., 6-minute walk trends in DMD studies)
  • Associated increases in bone mineral density in some models

Side effects (3)

  • Epistaxis (nosebleeds) and telangiectasias reported in clinical studies
  • Injection-site reactions (pain, pruritus, hematoma)
  • Potential vascular effects linked to broader ligand binding (e.g., BMP9/10 cross-reactivity in class)
No purchase links available